#

Biotechnology

: 158
BioNTech shares fell after unsuccessful trials of its mRNA drug / Photo: Kittyfly / Shutterstock
News·
BioNTech reported another setback in the development of cancer drugs. Its stock plummeted
“We hope this will be like COVID vaccines,” said Stacey Adam, a senior clinical officer at the Foundation for the NIH / Photo: Tada Images / Shutterstock
News·
Moderna hits four-year high as NYT reports U.S. cancer vaccine effort
Pacira’s EXPAREL treats acute postsurgical pain / Photo: Unsplash/Roberto Sorin
Small Caps·
Pacira soars 44% as Viatris agrees to buy biotech to boost non-opioid pain portfolio
Cathie Wood, through her investment firm ARK Invest, is one of the largest and most influential investors in biotechs using AI / Photo: Facebook / ARK Invest
Small Caps·
AI can halve drug development time. Here are 3 smaller AI biotechs Cathie Wood likes.
The company plans to use the proceeds to advance its lead drug candidate, which is in early trials in patients with moderate or severe atopic dermatitis / Photo: Unsplash/Testalize.me
Small Caps·
+1
·
TRex Bio IPO: LLY-backed biotech focused on autoimmune, inflammatory diseases debuts
Year to data, ArriVent stock has lost a quarter of its value / Photo: Shutterstock.com
Small Caps·
Chinese biotech ArriVent’s lung cancer drug fails in trial; stock plummets 47%
Iovance shares surged after the biotech raised its full-year revenue guidance, thanks to rising demand for a pair of melanoma treatments / Photo: Michael Vi / Shutterstock.com
Small Caps·
Small caps last week: Iovance ups guidance, Accelevation IPO, Burry boosts SFM stake
Innodata advanced after a Hunterbrook report said the data company may be helping train Muse / Photo: Erlin Diah / Shutterstock.com
Small Caps·
Small caps last week: Innodata linked to Muse, Viking data, higher rates hit segment
Hugo Boss board chair, Stephan Sturm, will step down after Frasers Group reached a 47.89% stake in Hugo Boss and began reviewing its support for him / Photo: Vytautas Kielaitis / Shutterstock.com
Small Caps·
Small caps last week: Hugo Boss shakeup, anxiety pill success, LuxExperience sales
The U.S. FDA approved Ultragenyxs first-in-disease gene therapy / Photo: Ultragenyx
Small Caps·
FDA approves rare-disease gene therapy, buoying producer Ultragenyx and others
Electra plans to use the proceeds from its IPO to fund clinical trials. Photo: FaceStock/Shutterstock
News·
Electra IPO: Shares of the developer of treatments for immune disorders and cancer are now available
The drug targets non-small cell lung cancer, a form of treatment-resistant lung cancer for which no approved oral targeted therapies currently exist / Photo: LinkedIn / Nasdaq Exchange
Small Caps·
Newly public biotech BlossomHill rallies on updated trial data for lung cancer drug
Load more